Daily Endocrinology Research Analysis
Three high-impact endocrinology studies stand out today: a double-blind randomized feeding trial shows that timing unsaturated fat intake at lunch improves insulin sensitivity via the gut microbiota–bile acid axis; a multicenter randomized trial demonstrates an AI-driven insulin titration system is noninferior to senior endocrinologists in inpatient glucose control; and a randomized trial using digital twin co-adaptation for automated insulin delivery improves time-in-range and HbA1c in type 1 d
Summary
Three high-impact endocrinology studies stand out today: a double-blind randomized feeding trial shows that timing unsaturated fat intake at lunch improves insulin sensitivity via the gut microbiota–bile acid axis; a multicenter randomized trial demonstrates an AI-driven insulin titration system is noninferior to senior endocrinologists in inpatient glucose control; and a randomized trial using digital twin co-adaptation for automated insulin delivery improves time-in-range and HbA1c in type 1 diabetes.
Research Themes
- Chrononutrition and metabolic regulation via the gut microbiota–bile acid axis
- AI-enabled insulin titration and clinical decision support
- Digital twin co-adaptation for automated insulin delivery personalization
Selected Articles
1. Timing of unsaturated fat intake improves insulin sensitivity via the gut microbiota-bile acid axis: a randomized controlled trial.
In a 12-week double-blind randomized feeding trial in prediabetes, consuming unsaturated fat at lunch (vs dinner) improved insulin sensitivity and reduced postprandial insulin and free saturated fatty acids without increasing postprandial glucose. Multi-omics analyses implicated gut microbiota and bile acid pathways in mediating these effects.
Impact: This trial advances chrononutrition by showing that meal timing of unsaturated fats can biologically modulate insulin sensitivity via the microbiome–bile acid axis. It provides mechanistic and translational evidence for timing-specific dietary prescriptions in metabolic disease.
Clinical Implications: For patients with prediabetes or insulin resistance, prioritizing unsaturated fat at lunch may be a practical strategy to improve insulin sensitivity without affecting postprandial glucose, complementing macronutrient quality and energy targets.
Key Findings
- Lunch-timed unsaturated fat intake improved insulin sensitivity compared with dinner timing.
- Postprandial insulin and serum free saturated fatty acids decreased with lunch-timed USFA, while postprandial glucose did not differ between groups.
- Metagenomic and fecal metabolite profiles implicated gut microbiota–bile acid pathways in mediating metabolic benefits.
Methodological Strengths
- Double-blind, randomized, controlled 2×2 factorial feeding design with standardized meals
- Integrated multi-omics (metagenomics and fecal metabolomics) linking physiology to mechanisms
Limitations
- Modest sample size per arm (n=15) and 12-week duration limits long-term inference
- Primary analyses limited to participants with complete fecal samples; generalizability needs confirmation
Future Directions: Test lunch-timed unsaturated fat within diabetes prevention programs at scale, assess durability and cardiometabolic outcomes, and identify microbial and bile acid signatures predictive of response.
The timing of dietary total fat intake influences glucose homeostasis, however, the impact of unsaturated fat (USFA) intake has yet to be explored. This 12-week, double-blind, randomized, controlled, 2 × 2 factorial-designed feeding trial investigated the effects of timing (lunch or dinner) and types of dietary USFA (high monounsaturated fat or polyunsaturated fat diet) intake on glucose metabolism in seventy prediabetes participants (mean age, 57 years). Sixty participants with completed fecal samples were included in the final analysis (n = 15 for each group). Postprandial serum glucose was first primary outcome, postprandial insulin levels and insulin sensitivity indices were co-primary outcomes Secondary outcomes were continuous glucose levels, serum fatty acid profile, gut microbiome (metagenomic sequencing) and fecal metabolites. Results showed no significant differences in postprandial glucose between groups. However, USFA intake at lunch (vs. dinner) improved insulin sensitivity and reduced postprandial insulin and serum free saturated fatty acid (P
2. Real-Time AI-Assisted Insulin Titration System for Glucose Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial.
In a multicenter RCT of 149 inpatients with T2D, an AI clinical decision support system for insulin titration achieved noninferior time-in-range compared with senior endocrinologists over 5 days, with similar safety. Physicians reported high satisfaction due to clarity and time savings.
Impact: Demonstrates that AI-driven insulin titration can safely match expert clinicians in real time, addressing a key bottleneck in individualized inpatient glycemic control.
Clinical Implications: Hospitals can consider deploying AI decision support to standardize and scale insulin titration while maintaining safety, potentially freeing clinician time and improving consistency.
Key Findings
- AI-based insulin titration achieved 76.4% time-in-range vs 73.6% with senior physicians, meeting the prespecified noninferiority margin.
- No significant differences in adverse events between AI and physician-managed groups over 5 days.
- Physician users reported high satisfaction citing clarity, time savings, effectiveness, and safety.
Methodological Strengths
- Multicenter, randomized, single-blind noninferiority design with a prespecified margin
- Clinically meaningful primary endpoint (time-in-range) and registered protocol
Limitations
- Short 5-day inpatient intervention limits generalizability to outpatient and long-term settings
- Modest sample size and single-blind design
Future Directions: Evaluate AI titration in outpatient and perioperative settings, assess longer-term outcomes (hypoglycemia, length of stay, readmissions), and integrate with closed-loop systems.
IMPORTANCE: Type 2 diabetes (T2D) is one of the most prevalent chronic diseases in the world. Insulin titration for glycemic control in T2D is crucial but limited by the lack of personalized and real-time tools. OBJECTIVE: To examine whether an artificial intelligence-based insulin clinical decision support system (iNCDSS) for glycemic control in hospitalized patients with T2D is noninferior to standard insulin therapy administered by senior physicians. DESIGN, SETTING, AND PARTICIPANTS: This multicenter, single-blind, parallel randomized clinical trial (RCT) was conducted between October 1, 2021, and September 8, 2022, in endocrinology wards of 3 medical centers. Eligible participants were adults (aged ≥18 years) with glycated hemoglobin levels between 7.0% and 11.0% who had received antidiabetic treatments in the previous 3 months. INTERVENTIONS: Participants were randomized in a 1:1 ratio to receive insulin dosage titration by iNCDSS or senior endocrinology physicians for 5 consecutive days. MAIN OUTCOMES AND MEASURES: The primary outcome was the proportion of time in the target glucose range (70-180 mg/dL) during the 5-day study period; the noninferiority margin was 6 percentage points. Secondary outcomes included other glycemic control measurements and adverse events. RESULTS: A total of 149 participants (mean [SD] age, 64.2 [12.0] years; 84 male [56.4%]) were enrolled and randomized to the iNCDSS group (n = 75) or physician group (n = 74). The mean (SD) target glucose range (primary outcome) was 76.4% (16.4%) in the iNCDSS group and 73.6% (16.8%) in the physician group, which achieved the prespecified noninferiority criterion (estimated treatment difference, 2.7%; 95% CI, -2.7% to 8.0%). There were no significant differences in adverse events between the 2 groups. Most physicians were satisfied with the iNCDSS for its clear, time-saving, effective, and safe clinical support. CONCLUSIONS AND RELEVANCE: In this RCT of an iNCDSS, the system demonstrated noninferiority to senior endocrinology physicians in insulin titration in an inpatient setting, indicating its potential as a favorable tool for insulin titration in patients with T2D. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04642378.
3. Human-machine co-adaptation to automated insulin delivery: a randomised clinical trial using digital twin technology.
A 6-month randomized trial in 72 adults with T1D showed that biweekly digital twin–guided co-adaptation of automated insulin delivery improved time-in-range (72% to 77%) and reduced HbA1c (6.8% to 6.6%). Information feedback alone did not enhance AID performance.
Impact: Introduces an interactive digital twin paradigm enabling both algorithm and user adaptation, demonstrating measurable gains in glycemic control over standard AID.
Clinical Implications: Digital twin–assisted parameter optimization may be integrated into AID platforms to personalize control and improve outcomes without additional user burden.
Key Findings
- Digital twin–based biweekly optimization increased time-in-range from 72% to 77% (p<0.01).
- HbA1c decreased from 6.8% to 6.6% during co-adaptation.
- Information feedback alone did not improve outcomes beyond standard AID.
Methodological Strengths
- Randomized clinical trial with 6-month duration reflecting real-world AID use
- Clear primary outcome (time-in-range) and quantified HbA1c improvement
Limitations
- Sample size modest (n=72) and potential selection bias of motivated AID users
- Details on safety endpoints and hypoglycemia burden are limited in the summary
Future Directions: Assess scalability of digital twin co-adaptation across diverse AID systems, quantify hypoglycemia endpoints, and explore cost-effectiveness and real-world deployment.
Most automated insulin delivery (AID) algorithms do not adapt to the changing physiology of their users, and none provide interactive means for user adaptation to the actions of AID. This randomised clinical trial tested human-machine co-adaptation to AID using new 'digital twin' replay simulation technology. Seventy-two individuals with T1D completed the 6-month study. The two study arms differed by the order of administration of information feedback (widely used metrics and graphs) and in silico co-adaptation routine, which: (i) transmitted AID data to a cloud application; (ii) mapped each person to their digital twin; (iii) optimized AID control parameters bi-weekly, and (iv) enabled users to experiment with what-if scenarios replayed via their own digital twins. In silico co-adaptation improved the primary outcome, time-in-range (3.9-10 mmol/L), from 72 to 77 percent (p < 0.01) and reduced glycated haemoglobin from 6.8 to 6.6 percent. Information feedback did not have additional effect to AID alone. (Clinical Trials Registration: NCT05610111 (November 10, 2022)).